Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) Convidecia®

Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) Convidecia®
Product Description

The third-generation technology

Produce humoral and cellular immunity

Stably stored and transported at 2–8°C

WHO Granted Emergency Use Listing (EUL) For Convidecia®

Approved in over 10 countries

CanSino Biologics Inc.

  • CN
  • 2024
    On CPHI since
  • 1
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Technology
Specifications
  • Model
    Solution for Intramuscular Injection

CanSino Biologics Inc.

  • CN
  • 2024
    On CPHI since
  • 1
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Technology

More Products from CanSino Biologics Inc. (4)